MedTrace Logo

Efficacy of 1540 Nanometer Erbium Glass Laser to Improve Benign Dermatofibromas

NCT03392935 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-05-08

Study results available
· View outcomes & findings →

Summary

This study is to find a more effective treatment for itchy, painful or unsightly dermatofibromas, that will improve symptoms of itch and/or pain and/or improve the appearance of dermatofibromas. This is an open-label study where subjects will receive a laser treatment at week 0, and week 4, and then 2 additional follow-up visits. Photographs will be taken at each visit and rated by blinded reviewers after the study to determine efficacy.

Conditions

  • Dermatofibroma of Skin

Interventions

DEVICE

1540 nanometer Erbium glass laser

Subjects will receive laser treatment by dermatologist at week 0 and week 4.

Sponsors & Collaborators

Principal Investigators

  • Karen Stolman, MD · Intermountain Health Care, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2021-03-31
Completion
2021-03-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03392935 on ClinicalTrials.gov